Friday, March 16, 2018

SESSION 1: COLON CANCER SCREENING

Enhanced Endoscopic Techniques to Improve Adenoma and Serrated Polyp Detection
*Douglas K. Rex, MD, MACG*
Outline enhanced endoscopic techniques including NBI, caps, chromo endoscopy, new scopes, and water immersion, used to improve polyp detection.

Optimal Methods for Colorectal Polypectomy
*Michael B. Wallace, MD, MPH, FACG*
Describe optimal methods to remove small and large polyps including new guidelines for cold snare polypectomy, review methods to resect large, lateral spreading polyps, including endoscopic mucosal resection (EMR), and discuss methods for removing polyps in difficult locations, such as the IC valve, behind folds, and anal verge.

SESSION 2: THERAPEUTIC ENDOSCOPY

The Role of Endoscopy for Bariatric Patients
*Victoria Gomez, MD*
Evaluate primary endoscopic therapies for obesity and techniques for the management of post-surgical weight regain, leaks, fistulae, and retained suture material.

Advances in EUS and Pancreatic Disorders
*Robert H. Hawes, MD, FACG*
Summarize how advances in EUS have improved the management of pancreatic cysts, pancreatic fluid collection, and biliary obstruction.

Advances in Endoscopic Resection, Top to Bottom
*Peter V. Draganov, MD, FACG*
Discuss EMR, ESD, cap methods, and the closure of perforations.

Saturday, March 17, 2018

SESSION 3: ESOPHAGEAL CONDITIONS

Treatment Endpoints for Eosinophilic Esophagitis
*Joel E. Richter, MD, MACG*
Recognize the symptoms and histology of eosinophilic esophagitis, and describe the role of allergists and nutritionists in reaching treatment endpoints.

Managing Barrett’s Esophagus After Ablation: Are We Done Now?
*Herbert C. Wolfsen, MD, FACG*
Apply the most recent guideline recommendations on management of Barrett’s patients after complete elimination of intestinal metaplasia; discuss interval of surveillance, treatment of recurrent metaplasia and/or dysplasia, the goal of antireflux therapy (PPI vs surgery), and chemoprevention (ASA).

GERD: Why, When, and How Do I Stop PPIs?
*Joel E. Richter, MD, MACG*
Explain the available data regarding side effects from long-term PPI use, and identify management strategies for when and how to stop it.
SESSION 4: FUNCTIONAL GI AND MOTILITY

Doctor, I Have SIBO. Really?
William D. Chey, MD, FACG
Describe the epidemiology, pathogenesis, clinical manifestations, diagnosis, and treatment of SIBO.

Pelvic Floor Dysfunction and Fecal Incontinence: Diagnosis and Therapy
Satish S.C. Rao, MD, PhD, FACG
Identify the various approaches to patients with suspected pelvic floor dysfunction and fecal incontinence, including diagnostic modalities and treatment options, including pelvic floor therapy.

New Options for Medical Management of IBS
William D. Chey, MD, FACG
Discuss new treatment strategies and medications including alternative natural remedies to manage IBS.

Saturday, March 18, 2018

SESSION 5: HEPATOLOGY

Non-invasive Assessment for Liver Fibrosis: Is This the End of Liver Biopsy?
Paul Martin, MD, FACG
Describe non-invasive alternatives to liver biopsy (elastography and chemical markers) for determining the degree of fibrosis in chronic liver disease.

Drug Induced Liver Injury: Review of the New ACG Guideline
Roberto J. Firpi, MD, MS, FACG
Identify evidence-based recommendations for the diagnosis and management of drug induced liver injury (DILI) with emphasis on when to refer patients to transplant centers.

HCV Update: Which Drug Do I Choose for the Treatment Naïve Patient?
Andrew P. Keaveny, MD
Outline the most recently approved medications for treatment of HCV, highlighting the treatment-naïve patient.

SESSION 6: IBD

Tailoring Anti-TNF Dosing Based on Drug and Anti-drug Antibody Level
Jason K. Hou, MD, MS, FACG
Describe clinical strategies tailoring anti-TNF closing based on drug and anti-drug antibody levels.

The Role of Advanced Imaging in IBD Colonoscopy
Michael F. Picco, MD, PhD, FACG
Discuss the role of advanced imaging colonoscopy in the assessment of inflammation, dysplasia detection, and management of IBD.

The Role of Biosimilars in Inflammatory Bowel Disease
Jason K. Hou, MD, MS, FACG
Explain the role, efficacy, and safety of biosimilars in management of IBD patients.